Amgen Inc., a biotechnology pioneer with a market cap of $159.6 billion, develops medicines for various conditions. While its stock lagged in the past year, it outperformed in 2025. Q1 results showed a 9.4% revenue increase, beating expectations. Analysts predict a 5.2% EPS growth for fiscal 2025, with a consensus “Moderate Buy” rating.

Analysts expect Amgen to deliver strong financial performance in fiscal 2025, with an adjusted EPS of $20.88. The stock has a consensus “Moderate Buy” rating, with a mean price target of $316.07 suggesting a 6.5% upside potential. Piper Sandler analyst David Amsellem reiterated an “Overweight” rating on AMGN with a price target of $328.

The stock has a 6.5% upside potential with a mean price target of $316.07. Piper Sandler analyst David Amsellem reiterated an “Overweight” rating with a $328 price target. The Street-high target of $400 represents a 34.7% premium. Analysts’ sentiment slightly shifted in the past three months.

Read more at Yahoo Finance: Do Wall Street Analysts Like Amgen Stock?